Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


China To Set Up Drug Innovation Structure Within Three Years

This article was originally published in PharmAsia News

Executive Summary

At the recent New Drug Innovation and CRO Forum in China, Vice Chairman of the Standing Committee of the National People's Congress Sang Guo-Wei reported that China's pharmaceutical industry's strategy is moving from imitating generic drugs to innovating on generics. Sang, who is also an academic at Chinese Academy of Engineering, noted that China has the basic requirements for creating new drugs, including talent, technology, industry and economic fundamentals. To date, the country has 150 medicines under clinical trials and 2,000 medicines ready for the clinical phase. China's goal is to establish an innovation system by stages: innovation transition phase from 2008 - 2010, when the government will invest at least 6.6 billion yuan $960 million) to set up the infrastructure; closing the gap between China and developed countries from 2011 - 2015; and by 2020, attaining the level of the developed countries. (Click here for more - Chinese Language)

You may also be interested in...

African Platform Eyes $750m Investment

Development Partners International, CDC Group and the European Bank for Reconstruction and Development have collaborated to create a “first of its kind, pan-African” generics platform built on the acquisition and combination of Egypt’s Adwia Pharmaceuticals and India’s Celon Laboratories. An initial $250m investment is to be followed by up to $500m in further funding.

Market Brief: Tissue-Engineered Wound Care Market Expected To Reach $1.9BN By 2024 Amid Rising Chronic Disease

The skin replacement market is led by three key players who have all been impacted by COVID-19, but the sector may see a quicker rebound than others as treatments cannot be deferred for a long time.

APACMed 2020: Healthineers Evolves Therapy Remit And Makes All Asia An Equal Priority

Siemens Healthineers' product mix of diagnostics and imaging products meant it was in the middle of a very dynamic situation when COVID-19 struck.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts